XNCR - Xencor Inc Stock Price, Fair Value and News

21.35USD-1.13 (-5.03%)Market Closed

Market Summary

USD21.35-1.13

Market Closed

-5.03%

XNCR Alerts

1 major insider sales recently.

Big fall in Revenue (Y/Y)
Losses in recent quarter

XNCR Stock Price

View Fullscreen

XNCR RSI Chart

XNCR Valuation

Market Cap

1.3B

Price/Earnings (Trailing)

-9.81

Price/Sales (Trailing)

8.12

EV/EBITDA

-27.99

Price/Free Cashflow

XNCR Price/Sales (Trailing)

XNCR Profitability

EBT Margin

-50.48%

Return on Equity

-21.91%

Return on Assets

-15.17%

Free Cashflow Yield

XNCR Fundamentals

XNCR Revenue

Revenue (TTM)

162.2M

Rev. Growth (Yr)

-32.63%

Rev. Growth (Qtr)

-71.35%

XNCR Earnings

Earnings (TTM)

-134.1M

Earnings Growth (Yr)

-18.45%

Earnings Growth (Qtr)

-214.28%

Breaking Down XNCR Revenue

Last 7 days

-12.2%

Last 30 days

4.3%

Last 90 days

11.7%

Trailing 12 Months

-20.2%

How does XNCR drawdown profile look like?

XNCR Financial Health

Current Ratio

7.08

Debt/Equity

0.02

Debt/Cashflow

4.84

XNCR Investor Care

Shares Dilution (1Y)

2.11%

Diluted EPS (TTM)

-2.18

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	162.2M	0	0	0
2023	98.1M	113.4M	145.3M	168.4M
2022	326.6M	289.4M	297.0M	164.6M
2021	124.3M	178.7M	163.0M	275.1M
2020	77.1M	70.7M	84.3M	122.7M
2019	182.7M	172.0M	164.7M	156.7M
2018	0	0	78.8M	77.8M
2017	83.8M	30.3M	29.5M	53.2M
2016	33.5M	98.5M	102.8M	87.5M
2015	8.8M	9.0M	11.7M	27.8M
2014	11.0M	7.9M	5.6M	9.5M
2013	9.7M	9.8M	10.0M	10.2M
2012	0	0	0	9.5M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Xencor Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 02, 2024	valente nancy	sold	-111,872	23.5768	-4,745	evp, chief development officer
Apr 09, 2024	cornelissen bart jan	acquired	-	-	42,265	sr. vice president & cfo
Mar 11, 2024	kuch john j	sold	-19,953	23.5018	-849	sr. vice president & cfo
Mar 11, 2024	eckert celia	sold	-19,976	23.5018	-850	svp, general counsel
Mar 11, 2024	desjarlais john r	sold	-30,082	23.5018	-1,280	sr. vice president & cso
Mar 11, 2024	dahiyat bassil i	sold	-64,418	23.5018	-2,741	president & ceo
Mar 06, 2024	gustafson kurt a	sold	-324,453	23.1752	-14,000	-
Mar 06, 2024	gustafson kurt a	acquired	160,950	10.73	15,000	-
Mar 05, 2024	desjarlais john r	acquired	-	-	20,724	sr. vice president & cso
Mar 05, 2024	eckert celia	acquired	-	-	13,089	svp, general counsel

Which funds bought or sold XNCR recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 10, 2024	CIBC Private Wealth Group, LLC	unchanged	-	12,119	384,981	-%
May 10, 2024	VANGUARD GROUP INC	added	3.6	11,485,700	155,154,000	-%
May 10, 2024	CITIGROUP INC	added	178	3,326,030	5,070,230	-%
May 10, 2024	OSAIC HOLDINGS, INC.	reduced	-55.65	-5,654	4,869	-%
May 10, 2024	JOHNSON & JOHNSON	unchanged	-	673,256	16,554,600	0.38%
May 10, 2024	Y-Intercept (Hong Kong) Ltd	new	-	582,351	582,351	0.04%
May 10, 2024	Covestor Ltd	added	72.22	1,000	1,000	-%
May 10, 2024	PNC Financial Services Group, Inc.	reduced	-7.33	-2,266	64,310	-%
May 10, 2024	Cannell & Spears LLC	new	-	278,838	278,838	0.01%
May 10, 2024	Campbell & CO Investment Adviser LLC	sold off	-100	-224,911	-	-%

Are Funds Buying or Selling XNCR?

Are funds buying XNCR calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own XNCR

No. of Funds

Unveiling Xencor Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 16, 2024	t. rowe price investment management, inc.	2.2%	1,351,367	SC 13G/A
Feb 14, 2024	t. rowe price investment management, inc.	2.2%	1,351,367	SC 13G
Feb 14, 2024	ecor1 capital, llc	8.7%	5,282,516	SC 13G/A
Feb 14, 2024	price t rowe associates inc /md/	5.7%	3,489,902	SC 13G/A
Feb 13, 2024	vanguard group inc	11.12%	6,767,249	SC 13G/A
Feb 12, 2024	primecap management co/ca/	14.62%	8,901,607	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Jan 25, 2024	state street corp	5.47%	3,326,856	SC 13G/A
Jan 19, 2024	blackrock inc.	18.6%	11,322,242	SC 13G/A
Feb 14, 2023	price t rowe associates inc /md/	5.4%	3,218,761	SC 13G/A

Recent SEC filings of Xencor Inc

View All Filings

Date Filed	Form Type	Document
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
May 03, 2024	4	Insider Trading
May 02, 2024	144	Notice of Insider Sale Intent
Apr 24, 2024	ARS	ARS
Apr 24, 2024	DEF 14A	DEF 14A
Apr 24, 2024	DEFA14A	DEFA14A
Apr 11, 2024	3	Insider Trading
Apr 11, 2024	4	Insider Trading
Apr 09, 2024	8-K	Current Report

Peers (Alternatives to Xencor Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.2B	6.8B	19.54%	-2.80%	-8.07	7.03	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.0B	2.0B	0.98%	-26.98%	-57.12	9.47	75.20%	68.82%
BMRN	15.3B	2.5B	-12.72%	-14.31%	74.39	6.18	13.74%	186.89%
INCY	12.9B	3.8B	6.98%	-11.75%	17.35	3.43	8.58%	129.81%
MID-CAP
BBIO	5.3B	107.9M	6.22%	110.41%	-9.76	48.09	54.84%	-28.31%
APLS	5.2B	524.1M	-16.95%	-51.10%	-12.51	9.96	394.93%	39.61%
AXSM	3.6B	251.0M	9.36%	-4.29%	-12.12	14.31	73.58%	-86.73%
ARWR	2.7B	240.7M	-10.69%	-43.90%	-5.82	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-11.38%	-29.25%	-1.5K	3.08	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	6.64%	20.67%	29.44	4.66	60.38%	-34.49%
NVAX	1.8B	996.6M	206.31%	55.15%	-4.62	1.85	-26.66%	65.49%
CRBP	458.7M	881.7K	5.07%	336.18%	-13.59	481.06	-77.61%	33.36%
INO	294.6M	4.9M	3.08%	29.79%	-2.36	60.54	-54.97%	48.23%
IBIO	15.6M	2.1M	-10.40%	79.21%	-0.67	7.61	-13.45%	69.54%

Xencor Inc News

Latest updates

Xencor Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-71.3%	12,800,000	44,670,000	59,164,000	45,523,000	19,000,000	21,609,500	27,300,000	30,175,000	85,495,000	153,998,000	19,683,000	67,447,000	34,000,000	41,854,000	35,366,000	13,089,000	32,385,000	3,508,000	21,760,000	19,485,000	111,939,000
Operating Expenses	-11.3%	70,660,000	79,698,000	77,432,000	71,520,000	78,327,000	64,202,000	65,647,000	58,175,000	59,029,000	62,363,500	60,983,000	58,360,000	49,637,000	55,552,000	52,088,000	50,689,000	41,162,000	34,088,500	36,036,000	39,057,000	33,695,000
S&GA Expenses	-100.0%	-	15,478,000	12,493,000	11,460,000	13,948,000	12,751,000	12,374,000	11,091,000	11,273,000	11,375,000	10,373,000	8,863,000	8,226,000	7,603,000	7,636,000	7,231,000	7,219,000	6,749,500	6,266,000	5,758,000	5,512,000
R&D Expenses	-11.4%	56,873,000	64,220,000	64,939,000	60,060,000	64,379,000	51,451,000	53,273,000	47,084,000	47,756,000	50,988,500	50,610,000	49,497,000	41,411,000	47,949,000	44,452,000	43,458,000	33,943,000	27,339,000	29,770,000	33,299,000	28,183,000
EBITDA Margin	7.0%	-0.29	-0.31	0.20	0.07	0.05	0.01	0.00	0.06	0.05	0.05	-0.57	-0.34	-	-	-	-	-	-	-	-	-
Interest Expenses	7.4%	7,471,000	6,954,000	5,016,000	3,764,000	2,892,000	2,068,000	1,379,000	717,000	653,000	291,000	196,000	147,000	215,000	712,000	1,423,000	2,090,000	3,039,000	3,418,500	3,699,000	3,615,000	2,886,000
Income Taxes	-100.0%	-	5,811,000	-	-	-	-415,000	1,100,000	-	-	-	-	-	-	-	-	-	-	-288,000	-350,000	50,000	900,000
Earnings Before Taxes	100.0%	-	-13,453,000	-24,269,000	-	-	-12,457,000	-31,671,000	-	-	73,061,000	-40,191,000	-	-	-13,691,000	-12,550,000	-35,018,000	-8,074,000	-27,200,000	-10,574,000	-15,984,000	80,945,000
EBT Margin	-3.8%	-0.50	-0.49	0.03	-0.10	-0.11	-0.07	-0.04	0.02	0.02	0.02	-0.62	-0.39	-	-	-	-	-	-	-	-	-
Net Income	-214.3%	-68,033,000	-21,647,000	-24,269,000	-20,189,000	-57,436,000	-8,324,500	-32,759,000	-35,798,000	17,983,000	73,105,500	-40,191,000	52,136,000	-2,464,000	-13,691,000	-12,550,000	-34,591,000	-8,179,000	-26,912,000	-10,224,000	-16,034,000	80,045,000
Net Income Margin	-12.7%	-0.83	-0.73	-0.76	-1.05	-1.37	-0.36	0.08	0.05	0.32	0.30	-0.03	0.13	-	-	-	-	-	-	-	-	-
Free Cashflow	-130.7%	-55,390,000	180,226,000	-30,113,000	-42,053,000	-41,397,000	-34,397,000	-15,253,000	31,915,000	3,726,000	55,470,000	-41,768,000	-11,937,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-7.2%	884	953	778	778	803	846	835	851	858	838	697	696	693	703	646	645	667	670	686	685	697
Current Assets	-9.8%	562	623	571	594	630	675	668	586	506	424	330	481	591	638	571	603	588	558	574	527	489
Cash Equivalents	-41.6%	31.00	54.00	53.00	35.00	72.00	54.00	53.00	49.00	78.00	143	41.00	116	177	164	58.00	110	74.00	50.00	51.00	33.00	22.00
Net PPE	-3.9%	64.00	66.00	68.00	68.00	67.00	59.00	51.00	39.00	28.00	28.00	24.00	23.00	22.00	22.00	20.00	16.00	17.00	16.00	14.00	12.00	11.00
Liabilities	-4.1%	272	284	109	99.00	120	119	113	109	95.00	105	78.00	49.00	109	131	78.00	74.00	74.00	77.00	76.00	77.00	87.00
Current Liabilities	-6.3%	79.00	85.00	53.00	45.00	65.00	64.00	90.00	75.00	61.00	71.00	44.00	46.00	100	121	70.00	66.00	66.00	67.00	64.00	64.00	73.00
Long Term Debt	-14.7%	12.00	15.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	15.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-8.5%	612	669	669	679	684	727	723	742	763	734	619	647	584	572	568	571	593	593	610	608	610
Retained Earnings	-14.7%	-532	-464	-445	-421	-399	-338	-326	-293	-259	-283	-356	-315	-368	-365	-352	-339	-304	-296	-269	-259	-243
Additional Paid-In Capital	1.2%	1,144	1,131	1,114	1,101	1,086	1,072	1,058	1,044	1,029	1,018	975	962	951	938	919	908	896	888	878	865	852
Shares Outstanding	1.0%	62.00	61.00	61.00	61.00	60.00	60.00	60.00	60.00	59.00	58.00	58.00	58.00	-	-	-	-	-	-	-	-	-
Minority Interest	-200.6%	-0.34	0.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	1,502	-	-	-	1,624	-	-	-	2,000	-	-	-	1,844	-	-	-	2,292	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-130.5%	-55,258	181,206	-27,281	-38,200	-30,614	-24,431	-1,168	44,269	5,815	61,790	-39,023	-9,654	-29,966	17,084	-3,866	-27,682	9,460	-19,577	-6,477	109,156	-18,728
Share Based Compensation	-22.3%	11,421	14,697	12,896	13,563	12,599	12,745	12,760	12,603	10,805	10,389	8,943	9,350	8,293	8,558	8,318	8,231	6,512	7,178	9,514	9,303	5,856
Cashflow From Investing	115.9%	32,318	-203,130	45,326	-1,405	48,144	24,548	3,125	-75,639	-71,759	7,860	-38,848	-53,309	38,048	78,779	-50,560	59,408	12,565	15,727	22,060	-102,430	13,673
Cashflow From Financing	-99.2%	186	22,983	356	1,921	922	1,171	1,287	2,513	731	32,630	3,229	1,840	5,339	9,587	2,986	4,000	1,471	2,973	3,049	3,973	667

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

XNCR Income Statement

2023-12-31

Consolidated Statements of Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenue
Collaborations, licenses, milestones, and royalties	$ 168,338	$ 164,579	$ 275,111
Operating expenses
Research and development	253,598	199,563	192,507
General and administrative	53,379	47,489	38,837
Total operating expenses	306,977	247,052	231,344
Income (loss) from operations	(138,639)	(82,473)	43,767
Other income (expense)
Interest income, net	18,626	4,817	849
Other expense, net	(31)	(286)	(1,274)
Gain (loss) on equity securities, net	(395)	23,434	39,289
Total other income, net	18,200	27,965	38,864
Income (loss) before income tax	(120,439)	(54,508)	82,631
Income tax expense	5,811	673	0
Net income (loss)	(126,250)	(55,181)	82,631
Net loss attributable to non-controlling interest	(163)	0	0
Net income (loss) attributable to Xencor, Inc.	$ (126,087)	$ (55,181)	$ 82,631
Net income (loss) per common share attributable to Xencor, Inc.:
Basic (in dollars per share)	$ (2.08)	$ (0.93)	$ 1.42
Diluted (in dollars per share)	$ (2.08)	$ (0.93)	$ 1.37
Weighted average common shares used to compute net income (loss) per share attributable to Xencor, Inc.
Basic (in shares)	60,503,283	59,652,461	58,379,641
Diluted (in shares)	60,503,283	59,652,461	60,495,455

XNCR Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 53,790	$ 53,942
Marketable debt securities	497,725	526,689
Marketable equity securities	42,210	42,431
Accounts receivable	11,290	28,997
Prepaid expenses and other current assets	18,145	23,283
Total current assets	623,160	675,342
Property and equipment, net	66,124	59,183
Patents, licenses, and other intangible assets, net	18,663	18,500
Restricted cash	380	0
Marketable debt securities - long term	145,512	3,826
Equity securities	64,210	54,383
Right of use asset	33,995	34,419
Other assets	648	613
Total assets	952,692	846,266
Current liabilities
Accounts payable	13,914	10,088
Accrued expenses	23,564	18,728
Income tax payable	5,782	0
Lease liabilities	3,435	4,708
Deferred revenue	0	30,320
Deferred income	31,682	0
Debt	6,332	0
Total current liabilities	84,709	63,844
Lease liabilities, net of current portion	59,025	54,926
Deferred income, net of current portion	125,183	0
Debt, net of current portion	14,642	0
Total liabilities	283,559	118,770
Commitments and contingencies (see note 9)
Stockholders’ equity
Preferred stock, $0.01 par value: 10,000,000 authorized shares; -0- issued and outstanding shares at December 31, 2023 and 2022	0	0
Common stock, $0.01 par value: 200,000,000 authorized shares; 60,998,191 issued and outstanding shares at December 31, 2023 and 59,997,713 issued and outstanding at December 31, 2022	611	601
Additional paid-in capital	1,131,266	1,072,132
Accumulated other comprehensive income	1,291	(6,952)
Accumulated deficit	(464,372)	(338,285)
Total stockholders’ equity attributable to Xencor, Inc.	668,796	727,496
Non-controlling interest	337	0
Total stockholders' equity	669,133	727,496
Total liabilities and stockholders’ equity	$ 952,692	$ 846,266

About Xencor Inc

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ib clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; Novartis XmAb, which is in Phase I clinical trial; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.

CEO	Dr. Bassil I. Dahiyat Ph.D.
WEBSITE	xencor.com
INDUSTRY	Biotechnology
EMPLOYEES	281

Xencor Inc Frequently Asked Questions

What is the ticker symbol for Xencor Inc? What does XNCR stand for in stocks?

XNCR is the stock ticker symbol of Xencor Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Xencor Inc (XNCR)?

As of Mon May 13 2024, market cap of Xencor Inc is 1.32 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of XNCR stock?

You can check XNCR's fair value in chart for subscribers.

What is the fair value of XNCR stock?

You can check XNCR's fair value in chart for subscribers. The fair value of Xencor Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Xencor Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for XNCR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Xencor Inc a good stock to buy?

The fair value guage provides a quick view whether XNCR is over valued or under valued. Whether Xencor Inc is cheap or expensive depends on the assumptions which impact Xencor Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for XNCR.

What is Xencor Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon May 13 2024, XNCR's PE ratio (Price to Earnings) is -9.81 and Price to Sales (PS) ratio is 8.12. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. XNCR PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Xencor Inc's stock?

In the past 10 years, Xencor Inc has provided 0.102 (multiply by 100 for percentage) rate of return.